Replies to post #248749 on NorthWest Biotherapeutics Inc (NWBO)

[sukus]

Thanks Senti for the reply. I remembered that Optune used two year data to estimate 3, 4 and 5 year survival. But I need to find that article to be sure. But you had confirmed it with the post below. When asked where is the 13% of 5 year OS coming from, Optune would need to be ready to support that claim.

The problem with the Optune data, as Flip has pointed out so many times, is that Novocure stopped the trial after everyone had been in it for just 2 years, basically freezing the estimated KM survival data at what it showed then, which was 29.3% for those 43 patients who'd worn the device for 90+ percent of the time. That's why the 3, 4 and 5 year survival percentage for those 43 patients is 29.3% every year. It was frozen in time. This KM data implies that at the 5th year, there were 13 from the 45 alive. The fact that Optune doesn't confirm this data, at the real-time 3, 4 and 5 year mark, argues that this isn't what ended up to be the case.

[flipper44]

The final data for Optune was cutoff just two years after the last patient enrolled. They used wild extrapolation and even wilder censoring games to pad longterm “results,” then stopped providing (aka: hid) further follow up data thereafter, and they instead resorted to data mining old data in an attempt to make it seem more complete.

DCVax-l is essentially at four years since the last patient was enrolled.